HRS Board Review Course: Part III (Pharmacology)-HRS Board Review Course: Part III (Pharmacology)

Video Transcription

Video Summary

The video features a board review session focusing on pharmacology related to electrophysiology (EP), specifically antiarrhythmic drugs. Dr. Ed Gerstenfeld from UC San Francisco is the first speaker, highlighting the complexities and nuances in managing arrhythmias, especially with antiarrhythmic drugs. He emphasizes the importance of guidelines, personal practices, and the need for careful consideration based on patient-specific factors, such as heart structure and presence of coronary artery disease. He discusses the potential use of drugs like Flecainide and Propafenone for atrial fibrillation (AF) and emphasizes caution with drugs like Amiodarone, highlighting their serious side effects. Dr. Jeanne Poole from the University of Washington then addresses drug-drug interactions, stressing the significance of the cytochrome P450 system and P-glycoprotein in drug metabolism, which can lead to various adverse drug interactions, including those involving commonly used drugs like warfarin and amiodarone. Dr. Breqena Begayner from Stanford University concludes the session with updates on newer pharmacological treatments for arrhythmias. She explores Ibradine's mechanisms, Atripamil's promising use for SVT and AF rates, and Vernakalant’s role in cardioversion, despite its non-approval in the US. This comprehensive session offers insights into drug choices, adverse effects, and emerging options for treating arrhythmias while balancing effectiveness and safety.

Keywords

pharmacology

electrophysiology

antiarrhythmic drugs

arrhythmias

drug interactions

cytochrome P450

Flecainide

Amiodarone

Ibradine

Vernakalant